Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Flexible design
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by canadapieton Sep 02, 2023 4:56am
120 Views
Post# 35617287

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Flexible design

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Flexible design
Exactly!!!! 

No partners, no insider buying, no cash, giga loan, stagnating sales???, .....

If you compare TH to other small biotech oncology companies, you have to wonder why 
anyone would invest in TH!!! 

But hey, glad to see people are gambling their money here and buying shares, i for one am waitnig for better signals.........!


GLA


PWIB123 - (9/1/2023 10:57:05 PM)
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Flexible design 
I want to believe in the science, and while it does appear they've set themselves up for the best possible success, they didn't get there the first time, no one has been willing to partner to-date, and there's zero insider buying.  If our own leadership team believed in it wholeheartedly, they'd be buying like crazy.  They are not.  Why is that?  The market can only assume one thing.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities